検索結果

临床试验信息 | 研究与开发 | 千寿制药株式会社

nical Trial Summaries ※Listed in order of date of first publication Medical Condition Phase Project Code Country Recruitment Status Access to Trial ID Allergic Conjunctivitis 2 SJP-0049 Japan Active, ...

nnounces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 was granted by the Ministry of Health, Labor and Welfare (HMLW) on June 19, 2024, as a...

ka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President...

Clinical Trial Summaries | Research & Development | SENJU Pharmaceutica

nical Trial Summaries ※Listed in order of date of first publication Medical Condition Phase Project Code Country Recruitment Status Access to Trial ID Allergic Conjunctivitis 2 SJP-0049 Japan Active, ...

sed to announce that “Avarept® Ophthalmic suspension 0.3%” (Generic Name: Motugivatrep, development code: SJP-0132, hereinafter: Product), discovered and licensed by Mochida Pharmaceutical Co., Ltd. (...